ondansetron (drug preventing vomiting) strip versus intravenous injection for ear and nose surgeries after operation

Ondansetron, orally disintegrating film versus intravenous injection for prevention of post operative nausea vomiting in middle ear and nasal surgeries- A randomized, placebo controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/03/003507

Enrollment

Registered

2013-03-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- surgery induced nausea vomiting

Interventions

Intervention1: ondansetron: 8mg ondansetron orally disintegrating film, single dose at the end of the surgery Intervention2: ondansetron: intravenous 8mg ondansetron, single dose at the end of the sur

Eligibility

Inclusion criteria

Inclusion criteria: elective middle ear and nasal surgeries under monitored anaesthesia care

Exclusion criteria

Exclusion criteria: raised serum urea and creatinine, advanced liver disease, history of chronic use of sedatives, narcotics or both, history of alcohol or drug abuse, or allergy to any of the study medications. Patients with history of motion sickness or PONV and refusal for inclusion in the study

Design outcomes

Primary

Measure	Time frame
reduction in incidence of post operative nausea vomitingTimepoint: 2, 6, 12, 18, and 24 h postoperatively	—

Secondary

Measure	Time frame
incidence of post operative pruritusTimepoint: 2, 6, 12, 18, and 24 h postoperatively	—

Countries

India

Contacts

Public ContactDr Uday Ambi

S Nijalingappa Medical college

udayambi@rediffmail.com08354235400

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026